India, April 21 -- Biocon Limited has received approval from Health Canada for its denosumab biosimilars—Bosaya™ and Vevzuo™—marking a key milestone in its global expansion strategy.
The approvals, granted on April 3, 2026, position Bosaya™ as a biosimilar to Prolia and Vevzuo™ as a biosimilar to Xgeva. Both are approved in standard formats for subcutaneous administration.
Denosumab-based therapies are widely used to improve bone health, particularly in treating osteoporosis and managing bone-related complications linked to cancer.
Bosaya™ has been approved for increasing bone mass and reducing fracture risk across multiple patient groups, including postmenopausal women, men with osteoporosis, an...